SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
DURHAM, N.C., March 29, 2016 -- In the release issued earlier today by Argos Therapeutics (Nasdaq:ARGS), please note that the "Selected Third Quarter 2015 Financial Results" header should be "Selected Fourth Quarter and Full-Year 2015 Financial Results." All other information in the press release remains the same.
Media contacts: Adam Daley Berry & Company Public Relations 212-253-8881 [email protected] Investor contact: John Menditto Argos Therapeutics, Inc. 919-908-0687 [email protected]
